Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin

Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 3, 1997, Pages 226-231

  Tarantino, Michael D ^a   Ross, Mitchell P ^b   Daniels, Todd M ^b   Nichols, William L ^b  

^a University of Louisville School of Medicine   (United States)

^b NONE

Author keywords

Bovine thrombin; Coagulation; Factor V; Inhibitor; Intravenous immune globulin

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING INHIBITOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; THROMBIN;

ANTIBODY TITER; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING TIME; BLOOD COMPONENT THERAPY; CARDIOVASCULAR SURGERY; CASE REPORT; CHILD; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANTIBODIES; CARDIAC SURGICAL PROCEDURES; CHILD; CROSS REACTIONS; FACTOR V; FACTOR V DEFICIENCY; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE COMPLICATIONS; THROMBIN;

EID: 0030921426     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199705000-00009     Document Type: Article

References (37)

1. Tidrick RT, Seegers WH, Warner ED. Clinical experience with thrombin as an hemostatic agent. Surgery 1943;14:191-6.
2. Diez-Martin J, Sikkink RA, Blackburn MN, et al. Acquired inhibitor of bovine thrombin. Blood 66 (Suppl) 1985;320a.
3. Diez-Martin J, Sikkink RA, Gilchrist GS, et al. Development of antibovine thrombin antibodies following neurosurgical procedures. Brit J Haematol 1990;74:369-70.
4. Flaherty MJ, Henderson R, Wener MH. Iatrogenic immunization with bovine thrombin: A mechanism for prolonged thrombin times after surgery. Ann Intern Med 1989;111:631-4.
5. Stricker RB, Lane PK, Leffert JD, et al. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 1988;72:1375-80.
6. Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990;76:2011-6.
7. Rapaport SI, Zivelin A, Minow RA, et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992;97:84-91.
8. Buclin T, Schmidt PM, Hauert J, et al. Acquired factor V inhibitor treated with intravenous immunoglobulins. Schweiz Med Wochenschr 1992;122:1968-70.
9. Nichols WL, Daniels TM, Fisher PK, et al. Antibodies to bovine thrombin and coagulation factor V associated with surgical use of topical bovine thrombin or fibrin "glue": a frequent finding. Blood 1993;82 (Suppl. 1):59a.
10. Cmolik BL, Spero JA, Magovern GJ, et al. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Cardiovasc Surg 1993;105:222-8.
11. Banninger H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993;85:528-32.
12. Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 1993;78:817-20.
13. Berruyer M, Amiral J, French P, et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg 1993;105:892-7.
14. Muntean W, Zenz W, Finding K, et al. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a 2-year-old child. Acta Paediatr 1994;83:84-7.
15. Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994;45:128-35.
16. Israels SJ, Israels ED. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. J Pediatr Hematol Oncol 1994;16:249-54.
17. Lawson JH, Pennell BJ, Olson JD, et al. Isolation and characterization of an acquired antithrombin antibody. Blood 1990;76:2249-57.
18. Kasper CK, Aledort L, Aronson D, et al. A more uniform measurement of factor VIII inhibitors. Thrombosis of Diathesis Haemorrhagia 1975;34:612.
19. Katzmann JA, Nesheim ME, Hibbard LS, et al. Isolation of functional human coagulation factor V using a hybridoma antibody. Proc Natl Acad Sci U S A 1981;78:162-6.
20. Ferguson JH, Johnston CL, Howell DA. A circulating inhibitor (anti-AcG) specific for the labile factor-V of the blood-clotting mechanism. Blood 1958;13:382-97.
21. Feinstein DI, Rapaport SI, McGehee WG, et al. Factor V anticoagulants: clinical, biochemical, and immunological observations. J Clin Invest 1970;49:1578-88.
22. Coots MC, Muhleman AF, Glueck HI. Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 1978;4:193-206.
23. Feinstein DI. Acquired inhibitors of Factor V. Thromb Haemost 1978;39:663-74.
24. Lazarchick J, Wolff M, Pepkowitz SH, et al. Factor V inhibitor associated with immune complex formation. Arch Pathol Lab Med 1986;110:448-51.
25. Nesheim ME, Nichols WL, Cole TL, et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986;77:405-15.
26. Arnaud E, Lafay M, Gaussem P, et al. An autoantibody directed against human thrombin anion-binding exosite in a patient with arterial thrombosis: effects on platelets, endothelial cells and protein C activation. Blood 1994;84:1843-50.
27. Ortel TL, Quinn-Allen ML, Charles LA, et al. Characterization of an acquired inhibitor to coagulation factor V. J Clin Invest 1992;90:2340-7.
28. Costa JM, Fiessinger JN, Capron L, et al. Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis. Thromb Haemost 1992;67:193-9.
29. Kapur A, Kelsey PR, Isaacs PE. Factor V inhibitor in thrombosis: Am J Hematol 1993;42:384-8.
30. Chediak J, Ashenhurst JB, Garlick I, et al. Successful management of bleeding in a patient with factor V inhibitor by platelet transfusion. Blood 1980;56:835-41.
31. Flores G, Cunningham-Rundles C, Newland AC, et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: Results in 73 patients. Am J Hematol 1993; 44:237-42.
32. Bussel J, Lalezari P, Hilgartner M, et al. Reversal of neutropenia with intravenous gammaglobulin in autoimmune neutropenia of infancy. Blood 1983;62:398-400.
33. Imbach P, d'Apuzzo V, Hirt A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31.
34. Sultan Y, Maisonneuve P, Kazatchkine MD, et al. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984;II: 765-8.
35. Schwartz RS, Gabriel DA, Aledort LM, et al. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995;86:797-804.
36. Kazatchkine MD, Kaveri SS, Nydegger UE, et al. Variable (V) region-mediated control of autoreactivity to factor VIII. In: Aledort LM, Hoyer LW, Lusher JM, et al., eds. Inhibitors to Coagulation Factors. New York: Plenum Press, 1995:223.
37. Nilsson IM, Sundqvist SB. Suppression of secondary antibody response by intravenous immunoglobulin and development of tolerance in a patient with haemophilia B antibodies. Scand J Haemotol Suppl 1984;33 (Suppl. 40):203-6.